Clinical and Immunologic Factors Associated With Bullous Pemphigoid Relapse During the First Year of Treatment
نویسندگان
چکیده
منابع مشابه
Bullous pemphigoid associated with mantle cell lymphoma.
BACKGROUND Bullous pemphigoid has developed in association with different types of malignant diseases, including a few cases of B-cell lymphoproliferative disorders. However, the paraneoplastic significance of this association is still controversial. OBSERVATIONS We describe a 39-year-old patient who presented with a bullous eruption and generalized lymphadenopathy. The results of histologic,...
متن کاملBullous pemphigoid associated with acquired hemophilia
daily for 1 week), pulse therapy with methylprednisolone (1000 mg/day for 3 days) and rituximab (100 mg/week for 2 weeks) were initially used for correcting the coagulopathy. Prednisolone (1 mg/kg/day) and cyclophosphamide (100 mg/ day) were prescribed as maintenance therapy. The coagulatory disorder improved after 2 months of treatment associated with reduction of factor VIII inhibitor to 35 B...
متن کاملBullous pemphigoid: clinical practice guidelines.
Bullous pemphigoid (BP) is an autoimmune subepidermal bullous disease in which autoantibodies are directed against components of the basement membrane. Most of these antibodies belong to the immunoglobulin G class and bind principally to 2 hemidesmosomal proteins: the 180-kD antigen (BP180) and the 230-kD antigen (BP230). It is the most common blistering disease in the adult population in devel...
متن کاملDoxycycline: a first-line treatment for bullous pemphigoid?
www.thelancet.com Published online March 6, 2017 http://dx.doi.org/10.1016/S0140-6736(17)30549-4 1 Bullous pemphigoid is the most common autoimmune blistering skin disease, and incidence is on the rise, due at least in part to its association with older age. Treatment of bullous pemphigoid presents a challenge to the clinician, as first-line treatment regimens—either oral corticosteroids or who...
متن کاملBullous pemphigoid during ustekinumab therapy
BP: Bullous pemphigoid TNF-a: tumor necrosis factor-alfa INTRODUCTION Ustekinumab, a monoclonal antibody that blocks interleukin-12 and interleukin-23, is a biological therapy used to treat moderate-to-severe psoriasis. Bullous pemphigoid (BP) induced by antietumor necrosis factor-alfa (TNF-a) agents has been described in the literature. No cases have been reported with ustekinumab. We report a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JAMA Dermatology
سال: 2014
ISSN: 2168-6068
DOI: 10.1001/jamadermatol.2013.5757